Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amphastar Pharmaceuticals (AMPH)
NASDAQ:AMPH
RESEARCH TOOLSreports
Holding AMPH?
Track your performance easily
AMPH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$36.56 - $65.92
Previous Close$48.64
Volume565.16K
Average Volume (3M)389.73K
Market Cap
$2.37B
Enterprise Value$2.77B
Total Cash (Recent Filing)$217.78M
Total Debt (Recent Filing)$620.58M
Price to Earnings (P/E)15.5
Beta0.65
Next Earnings
Nov 04, 2024EPS Estimate
$1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.14
Shares Outstanding48,675,822
10 Day Avg. Volume397,038
30 Day Avg. Volume389,727
Standard Deviation0.12
R-Squared0.14
Alpha0.00905
Financial Highlights & Ratios
Price to Book (P/B)3.40
Price to Sales (P/S)3.32
Price to Cash Flow (P/CF)8.60
P/FCF Ratio9.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.89
Enterprise Value/Gross Profit7.89
Enterprise Value/Ebitda9.25
Forecast
1Y Price Target
$59.75Price Target Upside20.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Amphastar Pharmaceuticals News
PremiumCompany Announcements
Amphastar Pharmaceuticals Advances Governance and Shareholder Value
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAMPH reported stronger-than-expected 2Q revenues of $182.4MM and higher adjusted EPS of $0.94 with adjusted net income of $48.7MM.
Future GrowthKey ANDA approvals in 2024/2025 are expected to drive the next leg of significant growth.
Key Products PerformanceKey branded products like BAQSIMI and Primatene Mist OTC are continuing to perform well, largely driven by volume growth.
Bears Say
Commercial ProspectsGx naloxone commercial prospects were downplayed while Gx Albuterol could see slower initial ramp.
Financial PerformanceMixed pipeline commentary and competition in generic glucagon lead to trim FY24E (-3%; now closer to consensus).
Market ConstraintsAMP-002 is expected to be capacity constrained for a protracted period in this two-player market.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
AMPH FAQ
What was Amphastar Pharmaceuticals’s price range in the past 12 months?
Amphastar Pharmaceuticals lowest stock price was $36.56 and its highest was $65.92 in the past 12 months.
What is Amphastar Pharmaceuticals’s market cap?
Currently, no data Available
When is Amphastar Pharmaceuticals’s upcoming earnings report date?
Amphastar Pharmaceuticals’s upcoming earnings report date is Nov 04, 2024 which is in 46 days.
How were Amphastar Pharmaceuticals’s earnings last quarter?
Amphastar Pharmaceuticals released its earnings results on Aug 07, 2024. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.772 by $0.168.
Is Amphastar Pharmaceuticals overvalued?
According to Wall Street analysts Amphastar Pharmaceuticals’s price is currently Undervalued.
Does Amphastar Pharmaceuticals pay dividends?
Amphastar Pharmaceuticals does not currently pay dividends.
What is Amphastar Pharmaceuticals’s EPS estimate?
Amphastar Pharmaceuticals’s EPS estimate is $1.01.
How many shares outstanding does Amphastar Pharmaceuticals have?
Amphastar Pharmaceuticals has 48,675,823 shares outstanding.
What happened to Amphastar Pharmaceuticals’s price movement after its last earnings report?
Amphastar Pharmaceuticals reported an EPS of $0.94 in its last earnings report, beating expectations of $0.772. Following the earnings report the stock price went up 13.294%.
Which hedge fund is a major shareholder of Amphastar Pharmaceuticals?
Among the largest hedge funds holding Amphastar Pharmaceuticals’s share is Hussman Strategic Advisors Inc. It holds Amphastar Pharmaceuticals’s shares valued at 3M.
---
Amphastar Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$59.75 (20.03% Upside)
$59.75 (20.03% Upside)
Blogger Sentiment
Bullish
AMPH Sentiment 90%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 17.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.27%
12-Months-Change
Fundamentals
Return on Equity
25.57%
Trailing 12-Months
Asset Growth
8.22%
Trailing 12-Months
Company Description
Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets and distributes enoxaparin, cortrosyn, amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment manufactures and distributes recombinant human insulin and porcine insulin. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.
---
AMPH Company Deck
---
AMPH Earnings Call
Q2 2024
0:00 / 0:00
---
AMPH Stock 12 Month Forecast
Average Price Target
$59.75
▲(20.03% Upside)
Technical Analysis
Best Analysts Covering AMPH
1 Year
1 Year Success Rate
15/17 ratings generated profit
1 Year Average Return
+28.84%
assigned a buy rating last month
Copying Tim Chiang's trades and holding each position for 1 Year would result in 88.24% of your transactions generating a profit, with an average return of +28.84% per trade.
---